| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| VRTX - Vertex Pharmaceuticals Inc | BUY | 780 @ USD 438.92 | USD 342,358 | The ETF bought 780 new shares of VRTX (Vertex Pharmaceuticals Inc). The shares were bought for an average price of 438.92 compared to the previous average buy price of 444.429. This is -1.2% lower than average price of previous purchases of VRTX. |
| GILD - Guild Esports Plc | BUY | 2,688 @ USD 121.26 | USD 325,947 | The ETF bought 2688 new shares of GILD (Guild Esports Plc). The shares were bought for an average price of 121.26 compared to the previous average buy price of 117.895. This is 2.9% higher than average price of previous purchases of GILD. |
| AMGN - Amgen Inc | BUY | 980 @ USD 330.03 | USD 323,429 | The ETF bought 980 new shares of AMGN (Amgen Inc). The shares were bought for an average price of 330.03 compared to the previous average buy price of 305.146. This is 8.2% higher than average price of previous purchases of AMGN. |
| REGN - Regeneron Pharmaceuticals Inc | BUY | 322 @ USD 741.92 | USD 238,898 | The ETF bought 322 new shares of REGN (Regeneron Pharmaceuticals Inc). The shares were bought for an average price of 741.92 compared to the previous average buy price of 655.932. This is 13.1% higher than average price of previous purchases of REGN. |
| AZN - AstraZeneca PLC | BUY | 1,816 @ USD 93.99 | USD 170,686 | The ETF bought 1816 new shares of AZN (AstraZeneca PLC). The shares were bought for an average price of 93.99 compared to the previous average buy price of 80.4581. This is 16.8% higher than average price of previous purchases of AZN. |
| ALNY - Alnylam Pharmaceuticals Inc | BUY | 412 @ USD 359.26 | USD 148,015 | The ETF bought 412 new shares of ALNY (Alnylam Pharmaceuticals Inc). The shares were bought for an average price of 359.26 compared to the previous average buy price of 388.077. This is -7.4% lower than average price of previous purchases of ALNY. |
| INSM - Insmed Inc | BUY | 664 @ USD 159.27 | USD 105,755 | The ETF bought 664 new shares of INSM (Insmed Inc). The shares were bought for an average price of 159.27 compared to the previous average buy price of 144.179. This is 10.5% higher than average price of previous purchases of INSM. |
| BIIB - Biogen Inc | BUY | 456 @ USD 168.57 | USD 76,868 | The ETF bought 456 new shares of BIIB (Biogen Inc). The shares were bought for an average price of 168.57 compared to the previous average buy price of 151.228. This is 11.5% higher than average price of previous purchases of BIIB. |
| RVMD - Revolution Medicines Inc | BUY | 602 @ USD 123.27 | USD 74,209 | The ETF bought 602 new shares of RVMD (Revolution Medicines Inc). The shares were bought for an average price of 123.27 compared to the previous average buy price of 52.9378. This is 132.9% higher than average price of previous purchases of RVMD. |
| ARGX - argenx NV ADR | BUY | 90 @ USD 813.24 | USD 73,192 | The ETF bought 90 new shares of ARGX (argenx NV ADR). The shares were bought for an average price of 813.24 compared to the previous average buy price of 723.704. This is 12.4% higher than average price of previous purchases of ARGX. |
| ILMN - Illumina Inc | BUY | 476 @ USD 145.3 | USD 69,163 | The ETF bought 476 new shares of ILMN (Illumina Inc). The shares were bought for an average price of 145.3 compared to the previous average buy price of 107.484. This is 35.2% higher than average price of previous purchases of ILMN. |
| INCY - Incyte Corporation | BUY | 610 @ USD 105.24 | USD 64,196 | The ETF bought 610 new shares of INCY (Incyte Corporation). The shares were bought for an average price of 105.24 compared to the previous average buy price of 82.8179. This is 27.1% higher than average price of previous purchases of INCY. |
| UTHR - United Therapeutics Corporation | BUY | 134 @ USD 471.99 | USD 63,247 | The ETF bought 134 new shares of UTHR (United Therapeutics Corporation). The shares were bought for an average price of 471.99 compared to the previous average buy price of 387.713. This is 21.7% higher than average price of previous purchases of UTHR. |
| MEDP - Medpace Holdings Inc | BUY | 88 @ USD 618.04 | USD 54,388 | The ETF bought 88 new shares of MEDP (Medpace Holdings Inc). The shares were bought for an average price of 618.04 compared to the previous average buy price of 453.319. This is 36.3% higher than average price of previous purchases of MEDP. |
| RPRX - Royalty Pharma Plc | BUY | 1,330 @ USD 39.72 | USD 52,828 | The ETF bought 1330 new shares of RPRX (Royalty Pharma Plc). The shares were bought for an average price of 39.72 compared to the previous average buy price of 36.8789. This is 7.7% higher than average price of previous purchases of RPRX. |
| ROIV - Roivant Sciences Ltd | BUY | 2,164 @ USD 23.3 | USD 50,421 | The ETF bought 2164 new shares of ROIV (Roivant Sciences Ltd). The shares were bought for an average price of 23.3 compared to the previous average buy price of 15.6669. This is 48.7% higher than average price of previous purchases of ROIV. |
| MRNA - Moderna Inc | BUY | 1,216 @ USD 39.36 | USD 47,862 | The ETF bought 1216 new shares of MRNA (Moderna Inc). The shares were bought for an average price of 39.36 compared to the previous average buy price of 28.3231. This is 39.0% higher than average price of previous purchases of MRNA. |
| VTRS - Viatris Inc | BUY | 3,584 @ USD 12.84 | USD 46,019 | The ETF bought 3584 new shares of VTRS (Viatris Inc). The shares were bought for an average price of 12.84 compared to the previous average buy price of 10.0665. This is 27.6% higher than average price of previous purchases of VTRS. |
| BBIO - BridgeBio Pharma Inc | BUY | 600 @ USD 76.26 | USD 45,756 | The ETF bought 600 new shares of BBIO (BridgeBio Pharma Inc). The shares were bought for an average price of 76.26 compared to the previous average buy price of 53.4491. This is 42.7% higher than average price of previous purchases of BBIO. |
| GH - Guardant Health Inc | BUY | 402 @ USD 111.98 | USD 45,016 | The ETF bought 402 new shares of GH (Guardant Health Inc). The shares were bought for an average price of 111.98 compared to the previous average buy price of 70.8869. This is 58.0% higher than average price of previous purchases of GH. |
| NBIX - Neurocrine Biosciences Inc | BUY | 310 @ USD 133.35 | USD 41,339 | The ETF bought 310 new shares of NBIX (Neurocrine Biosciences Inc). The shares were bought for an average price of 133.35 compared to the previous average buy price of 135.821. This is -1.8% lower than average price of previous purchases of NBIX. |
| ASND - Ascendis Pharma AS | BUY | 192 @ USD 215.04 | USD 41,288 | The ETF bought 192 new shares of ASND (Ascendis Pharma AS). The shares were bought for an average price of 215.04 compared to the previous average buy price of 187.812. This is 14.5% higher than average price of previous purchases of ASND. |
| SMMT - Summit Therapeutics PLC | BUY | 2,316 @ USD 17.27 | USD 39,997 | The ETF bought 2316 new shares of SMMT (Summit Therapeutics PLC). The shares were bought for an average price of 17.27 compared to the previous average buy price of 20.2173. This is -14.6% lower than average price of previous purchases of SMMT. |
| SNY - Sanofi ADR | BUY | 824 @ USD 47.47 | USD 39,115 | The ETF bought 824 new shares of SNY (Sanofi ADR). The shares were bought for an average price of 47.47 compared to the previous average buy price of 49.8115. This is -4.7% lower than average price of previous purchases of SNY. |
| IONS - Ionis Pharmaceuticals Inc | BUY | 504 @ USD 77.21 | USD 38,914 | The ETF bought 504 new shares of IONS (Ionis Pharmaceuticals Inc). The shares were bought for an average price of 77.21 compared to the previous average buy price of 58.2537. This is 32.5% higher than average price of previous purchases of IONS. |
| EXEL - Exelixis Inc | BUY | 834 @ USD 45.44 | USD 37,897 | The ETF bought 834 new shares of EXEL (Exelixis Inc). The shares were bought for an average price of 45.44 compared to the previous average buy price of 41.8548. This is 8.6% higher than average price of previous purchases of EXEL. |
| MDGL - Madrigal Pharmaceuticals Inc | BUY | 70 @ USD 495.88 | USD 34,712 | The ETF bought 70 new shares of MDGL (Madrigal Pharmaceuticals Inc). The shares were bought for an average price of 495.88 compared to the previous average buy price of 419.447. This is 18.2% higher than average price of previous purchases of MDGL. |
| RNA - Avidity Biosciences Inc | BUY | 468 @ USD 72.6 | USD 33,977 | The ETF bought 468 new shares of RNA (Avidity Biosciences Inc). The shares were bought for an average price of 72.6 compared to the previous average buy price of 51.9758. This is 39.7% higher than average price of previous purchases of RNA. |
| BNTX - BioNTech SE | BUY | 314 @ USD 106.07 | USD 33,306 | The ETF bought 314 new shares of BNTX (BioNTech SE). The shares were bought for an average price of 106.07 compared to the previous average buy price of 102.802. This is 3.2% higher than average price of previous purchases of BNTX. |
| BMRN - Biomarin Pharmaceutical Inc | BUY | 598 @ USD 55.07 | USD 32,932 | The ETF bought 598 new shares of BMRN (Biomarin Pharmaceutical Inc). The shares were bought for an average price of 55.07 compared to the previous average buy price of 57.0994. This is -3.6% lower than average price of previous purchases of BMRN. |
| JAZZ - Jazz Pharmaceuticals PLC | BUY | 190 @ USD 171.16 | USD 32,520 | The ETF bought 190 new shares of JAZZ (Jazz Pharmaceuticals PLC). The shares were bought for an average price of 171.16 compared to the previous average buy price of 137.266. This is 24.7% higher than average price of previous purchases of JAZZ. |
| ARWR - Arrowhead Pharmaceuticals Inc | BUY | 422 @ USD 66.25 | USD 27,958 | The ETF bought 422 new shares of ARWR (Arrowhead Pharmaceuticals Inc). The shares were bought for an average price of 66.25 compared to the previous average buy price of 31.9619. This is 107.3% higher than average price of previous purchases of ARWR. |
| AXSM - Axsome Therapeutics Inc | BUY | 156 @ USD 174.14 | USD 27,166 | The ETF bought 156 new shares of AXSM (Axsome Therapeutics Inc). The shares were bought for an average price of 174.14 compared to the previous average buy price of 126.164. This is 38.0% higher than average price of previous purchases of AXSM. |
| HALO - Halozyme Therapeutics Inc | BUY | 366 @ USD 71.82 | USD 26,286 | The ETF bought 366 new shares of HALO (Halozyme Therapeutics Inc). The shares were bought for an average price of 71.82 compared to the previous average buy price of 62.1868. This is 15.5% higher than average price of previous purchases of HALO. |
| KRYS - Krystal Biotech Inc | BUY | 90 @ USD 282.01 | USD 25,381 | The ETF bought 90 new shares of KRYS (Krystal Biotech Inc). The shares were bought for an average price of 282.01 compared to the previous average buy price of 182.068. This is 54.9% higher than average price of previous purchases of KRYS. |
| CYTK - Cytokinetics Inc | BUY | 380 @ USD 63.435 | USD 24,105 | The ETF bought 380 new shares of CYTK (Cytokinetics Inc). The shares were bought for an average price of 63.435 compared to the previous average buy price of 49.9307. This is 27.0% higher than average price of previous purchases of CYTK. |
| NUVL - Nuvalent Inc | BUY | 224 @ USD 106.16 | USD 23,780 | The ETF bought 224 new shares of NUVL (Nuvalent Inc). The shares were bought for an average price of 106.16 compared to the previous average buy price of 89.6815. This is 18.4% higher than average price of previous purchases of NUVL. |
| PRAX - Praxis Precision Medicines Inc | BUY | 78 @ USD 297.74 | USD 23,224 | The ETF bought 78 new shares of PRAX (Praxis Precision Medicines Inc). The shares were bought for an average price of 297.74 compared to the previous average buy price of 132.714. This is 124.3% higher than average price of previous purchases of PRAX. |
| RYTM - Rhythm Pharmaceuticals Inc | BUY | 208 @ USD 106.06 | USD 22,060 | The ETF bought 208 new shares of RYTM (Rhythm Pharmaceuticals Inc). The shares were bought for an average price of 106.06 compared to the previous average buy price of 84.8844. This is 24.9% higher than average price of previous purchases of RYTM. |
| PCVX - Vaxcyte Inc | BUY | 408 @ USD 48.04 | USD 19,600 | The ETF bought 408 new shares of PCVX (Vaxcyte Inc). The shares were bought for an average price of 48.04 compared to the previous average buy price of 45.3182. This is 6.0% higher than average price of previous purchases of PCVX. |
| PTCT - PTC Therapeutics Inc | BUY | 250 @ USD 75.64 | USD 18,910 | The ETF bought 250 new shares of PTCT (PTC Therapeutics Inc). The shares were bought for an average price of 75.64 compared to the previous average buy price of 62.2006. This is 21.6% higher than average price of previous purchases of PTCT. |
| COGT - Cogent Biosciences Inc | BUY | 478 @ USD 39.25 | USD 18,762 | The ETF bought 478 new shares of COGT (Cogent Biosciences Inc). The shares were bought for an average price of 39.25 compared to the previous average buy price of 20.8705. This is 88.1% higher than average price of previous purchases of COGT. |
| GPCR - Structure Therapeutics Inc. American Depositary Shares | BUY | 208 @ USD 85.02 | USD 17,684 | The ETF bought 208 new shares of GPCR (Structure Therapeutics Inc. American Depositary Shares). The shares were bought for an average price of 85.02 compared to the previous average buy price of 32.9342. This is 158.2% higher than average price of previous purchases of GPCR. |
| CRNX - Crinetics Pharmaceuticals Inc | BUY | 296 @ USD 56.43 | USD 16,703 | The ETF bought 296 new shares of CRNX (Crinetics Pharmaceuticals Inc). The shares were bought for an average price of 56.43 compared to the previous average buy price of 38.7861. This is 45.5% higher than average price of previous purchases of CRNX. |
| PTGX - Protagonist Therapeutics Inc | BUY | 194 @ USD 84.75 | USD 16,442 | The ETF bought 194 new shares of PTGX (Protagonist Therapeutics Inc). The shares were bought for an average price of 84.75 compared to the previous average buy price of 65.9513. This is 28.5% higher than average price of previous purchases of PTGX. |
| ALKS - Alkermes Plc | BUY | 514 @ USD 31.22 | USD 16,047 | The ETF bought 514 new shares of ALKS (Alkermes Plc). The shares were bought for an average price of 31.22 compared to the previous average buy price of 30.0354. This is 3.9% higher than average price of previous purchases of ALKS. |
| CRSP - Crispr Therapeutics AG | BUY | 296 @ USD 54.21 | USD 16,046 | The ETF bought 296 new shares of CRSP (Crispr Therapeutics AG). The shares were bought for an average price of 54.21 compared to the previous average buy price of 53.3054. This is 1.7% higher than average price of previous purchases of CRSP. |
| KYMR - Kymera Therapeutics Inc | BUY | 224 @ USD 71.12 | USD 15,931 | The ETF bought 224 new shares of KYMR (Kymera Therapeutics Inc). The shares were bought for an average price of 71.12 compared to the previous average buy price of 53.8343. This is 32.1% higher than average price of previous purchases of KYMR. |
| SRRK - Scholar Rock Holding Corp | BUY | 320 @ USD 46.53 | USD 14,890 | The ETF bought 320 new shares of SRRK (Scholar Rock Holding Corp). The shares were bought for an average price of 46.53 compared to the previous average buy price of 37.2178. This is 25.0% higher than average price of previous purchases of SRRK. |
| MIRM - Mirum Pharmaceuticals Inc | BUY | 160 @ USD 92.32 | USD 14,771 | The ETF bought 160 new shares of MIRM (Mirum Pharmaceuticals Inc). The shares were bought for an average price of 92.32 compared to the previous average buy price of 60.7527. This is 52.0% higher than average price of previous purchases of MIRM. |
| IMVT - Immunovant Inc | BUY | 546 @ USD 26 | USD 14,196 | The ETF bought 546 new shares of IMVT (Immunovant Inc). The shares were bought for an average price of 26 compared to the previous average buy price of 19.5139. This is 33.2% higher than average price of previous purchases of IMVT. |
| ACAD - ACADIA Pharmaceuticals Inc | BUY | 526 @ USD 26.53 | USD 13,955 | The ETF bought 526 new shares of ACAD (ACADIA Pharmaceuticals Inc). The shares were bought for an average price of 26.53 compared to the previous average buy price of 22.3238. This is 18.8% higher than average price of previous purchases of ACAD. |
| FOLD - Amicus Therapeutics Inc | BUY | 960 @ USD 14.31 | USD 13,738 | The ETF bought 960 new shares of FOLD (Amicus Therapeutics Inc). The shares were bought for an average price of 14.31 compared to the previous average buy price of 8.40156. This is 70.3% higher than average price of previous purchases of FOLD. |
| APGE - Apogee Therapeutics, Inc. Common Stock | BUY | 170 @ USD 80.75 | USD 13,728 | The ETF bought 170 new shares of APGE (Apogee Therapeutics, Inc. Common Stock). The shares were bought for an average price of 80.75 compared to the previous average buy price of 57.6677. This is 40.0% higher than average price of previous purchases of APGE. |
| CGON - CG Oncology, Inc. Common stock | BUY | 250 @ USD 53.07 | USD 13,268 | The ETF bought 250 new shares of CGON (CG Oncology, Inc. Common stock). The shares were bought for an average price of 53.07 compared to the previous average buy price of 33.9014. This is 56.5% higher than average price of previous purchases of CGON. |
| ADMA - ADMA Biologics Inc | BUY | 742 @ USD 17.5 | USD 12,985 | The ETF bought 742 new shares of ADMA (ADMA Biologics Inc). The shares were bought for an average price of 17.5 compared to the previous average buy price of 17.8307. This is -1.9% lower than average price of previous purchases of ADMA. |
| AMRX - Amneal Pharmaceuticals, Inc. Class A Common Stock | BUY | 980 @ USD 13.19 | USD 12,926 | The ETF bought 980 new shares of AMRX (Amneal Pharmaceuticals, Inc. Class A Common Stock). The shares were bought for an average price of 13.19 compared to the previous average buy price of 9.83079. This is 34.2% higher than average price of previous purchases of AMRX. |
| ACLX - Arcellx Inc | BUY | 180 @ USD 68.32 | USD 12,298 | The ETF bought 180 new shares of ACLX (Arcellx Inc). The shares were bought for an average price of 68.32 compared to the previous average buy price of 71.9502. This is -5.0% lower than average price of previous purchases of ACLX. |
| LGND - Ligand Pharmaceuticals Incorporated | BUY | 62 @ USD 196.08 | USD 12,157 | The ETF bought 62 new shares of LGND (Ligand Pharmaceuticals Incorporated). The shares were bought for an average price of 196.08 compared to the previous average buy price of 152.059. This is 28.9% higher than average price of previous purchases of LGND. |
| GRAL - GRAIL, LLC | BUY | 120 @ USD 97.44 | USD 11,693 | The ETF bought 120 new shares of GRAL (GRAIL, LLC). The shares were bought for an average price of 97.44 compared to the previous average buy price of 66.2864. This is 47.0% higher than average price of previous purchases of GRAL. |
| TERN - Tern Plc | BUY | 280 @ USD 36.98 | USD 10,354 | The ETF bought 280 new shares of TERN (Tern Plc). The shares were bought for an average price of 36.98 compared to the previous average buy price of 12.7424. This is 190.2% higher than average price of previous purchases of TERN. |
| BEAM - Beam Therapeutics Inc | BUY | 316 @ USD 32.05 | USD 10,128 | The ETF bought 316 new shares of BEAM (Beam Therapeutics Inc). The shares were bought for an average price of 32.05 compared to the previous average buy price of 22.2946. This is 43.8% higher than average price of previous purchases of BEAM. |
| VCYT - Veracyte Inc | BUY | 246 @ USD 41 | USD 10,086 | The ETF bought 246 new shares of VCYT (Veracyte Inc). The shares were bought for an average price of 41 compared to the previous average buy price of 35.5078. This is 15.5% higher than average price of previous purchases of VCYT. |
| ARQT - Arcutis Biotherapeutics Inc | BUY | 382 @ USD 26.36 | USD 10,070 | The ETF bought 382 new shares of ARQT (Arcutis Biotherapeutics Inc). The shares were bought for an average price of 26.36 compared to the previous average buy price of 20.6537. This is 27.6% higher than average price of previous purchases of ARQT. |
| IDYA - Ideaya Biosciences Inc | BUY | 272 @ USD 36.06 | USD 9,808 | The ETF bought 272 new shares of IDYA (Ideaya Biosciences Inc). The shares were bought for an average price of 36.06 compared to the previous average buy price of 26.7475. This is 34.8% higher than average price of previous purchases of IDYA. |
| XENE - Xenon Pharmaceuticals Inc | BUY | 240 @ USD 40.74 | USD 9,778 | The ETF bought 240 new shares of XENE (Xenon Pharmaceuticals Inc). The shares were bought for an average price of 40.74 compared to the previous average buy price of 37.9473. This is 7.4% higher than average price of previous purchases of XENE. |
| TARS - Tarsus Pharmaceuticals Inc | BUY | 132 @ USD 73.65 | USD 9,722 | The ETF bought 132 new shares of TARS (Tarsus Pharmaceuticals Inc). The shares were bought for an average price of 73.65 compared to the previous average buy price of 57.9402. This is 27.1% higher than average price of previous purchases of TARS. |
| VERA - Vera Therapeutics Inc | BUY | 198 @ USD 46.28 | USD 9,163 | The ETF bought 198 new shares of VERA (Vera Therapeutics Inc). The shares were bought for an average price of 46.28 compared to the previous average buy price of 31.2019. This is 48.3% higher than average price of previous purchases of VERA. |
| SUPN - Supernus Pharmaceuticals Inc | BUY | 178 @ USD 50.26 | USD 8,946 | The ETF bought 178 new shares of SUPN (Supernus Pharmaceuticals Inc). The shares were bought for an average price of 50.26 compared to the previous average buy price of 40.1604. This is 25.1% higher than average price of previous purchases of SUPN. |
| EWTX - Edgewise Therapeutics Inc | BUY | 330 @ USD 26.6 | USD 8,778 | The ETF bought 330 new shares of EWTX (Edgewise Therapeutics Inc). The shares were bought for an average price of 26.6 compared to the previous average buy price of 18.3364. This is 45.1% higher than average price of previous purchases of EWTX. |
| DNLI - Denali Therapeutics Inc | BUY | 456 @ USD 18.78 | USD 8,564 | The ETF bought 456 new shares of DNLI (Denali Therapeutics Inc). The shares were bought for an average price of 18.78 compared to the previous average buy price of 16.2621. This is 15.5% higher than average price of previous purchases of DNLI. |
| ERAS - Erasca Inc | BUY | 886 @ USD 9.56 | USD 8,470 | The ETF bought 886 new shares of ERAS (Erasca Inc). The shares were bought for an average price of 9.56 compared to the previous average buy price of 2.21911. This is 330.8% higher than average price of previous purchases of ERAS. |
| ADPT - Adaptive Biotechnologies Corp | BUY | 476 @ USD 17.78 | USD 8,463 | The ETF bought 476 new shares of ADPT (Adaptive Biotechnologies Corp). The shares were bought for an average price of 17.78 compared to the previous average buy price of 13.6525. This is 30.2% higher than average price of previous purchases of ADPT. |
| IRON - Ironveld Plc | BUY | 116 @ USD 71.04 | USD 8,241 | The ETF bought 116 new shares of IRON (Ironveld Plc). The shares were bought for an average price of 71.04 compared to the previous average buy price of 66.8911. This is 6.2% higher than average price of previous purchases of IRON. |
| APLS - Apellis Pharmaceuticals Inc | BUY | 394 @ USD 20.53 | USD 8,089 | The ETF bought 394 new shares of APLS (Apellis Pharmaceuticals Inc). The shares were bought for an average price of 20.53 compared to the previous average buy price of 21.3401. This is -3.8% lower than average price of previous purchases of APLS. |
| SYRE - Spyre Therapeutics Inc. | BUY | 242 @ USD 33.09 | USD 8,008 | The ETF bought 242 new shares of SYRE (Spyre Therapeutics Inc.). The shares were bought for an average price of 33.09 compared to the previous average buy price of 24.9617. This is 32.6% higher than average price of previous purchases of SYRE. |
| TVTX - Travere Therapeutics Inc | BUY | 278 @ USD 28.4 | USD 7,895 | The ETF bought 278 new shares of TVTX (Travere Therapeutics Inc). The shares were bought for an average price of 28.4 compared to the previous average buy price of 24.8206. This is 14.4% higher than average price of previous purchases of TVTX. |
| TWST - Twist Bioscience Corp | BUY | 190 @ USD 41.27 | USD 7,841 | The ETF bought 190 new shares of TWST (Twist Bioscience Corp). The shares were bought for an average price of 41.27 compared to the previous average buy price of 34.6652. This is 19.1% higher than average price of previous purchases of TWST. |
| MLYS - Mineralys Therapeutics, Inc. Common Stock | BUY | 246 @ USD 31.38 | USD 7,719 | The ETF bought 246 new shares of MLYS (Mineralys Therapeutics, Inc. Common Stock). The shares were bought for an average price of 31.38 compared to the previous average buy price of 26.6651. This is 17.7% higher than average price of previous purchases of MLYS. |
| TXG - 10X Genomics Inc | BUY | 362 @ USD 21.2 | USD 7,674 | The ETF bought 362 new shares of TXG (10X Genomics Inc). The shares were bought for an average price of 21.2 compared to the previous average buy price of 13.8795. This is 52.7% higher than average price of previous purchases of TXG. |
| TXG - Terex Corporation | BUY | 362 @ USD 21.2 | USD 7,674 | The ETF bought 362 new shares of TXG (Terex Corporation). The shares were bought for an average price of 21.2 compared to the previous average buy price of 13.8795. This is 52.7% higher than average price of previous purchases of TXG. |
| OCUL - Ocular Therapeutix Inc | BUY | 664 @ USD 11.28 | USD 7,490 | The ETF bought 664 new shares of OCUL (Ocular Therapeutix Inc). The shares were bought for an average price of 11.28 compared to the previous average buy price of 11.0183. This is 2.4% higher than average price of previous purchases of OCUL. |
| RXRX - Recursion Pharmaceuticals Inc | BUY | 1,604 @ USD 4.64 | USD 7,443 | The ETF bought 1604 new shares of RXRX (Recursion Pharmaceuticals Inc). The shares were bought for an average price of 4.64 compared to the previous average buy price of 5.2735. This is -12.0% lower than average price of previous purchases of RXRX. |
| WVE - Wave Life Sciences Ltd | BUY | 522 @ USD 14.07 | USD 7,345 | The ETF bought 522 new shares of WVE (Wave Life Sciences Ltd). The shares were bought for an average price of 14.07 compared to the previous average buy price of 8.60272. This is 63.6% higher than average price of previous purchases of WVE. |
| DYN - Dyne Therapeutics Inc | BUY | 446 @ USD 16.42 | USD 7,323 | The ETF bought 446 new shares of DYN (Dyne Therapeutics Inc). The shares were bought for an average price of 16.42 compared to the previous average buy price of 15.0497. This is 9.1% higher than average price of previous purchases of DYN. |
| DYN - DYNAGREEN EN.PR.GR.H YC 1 | BUY | 446 @ USD 16.42 | USD 7,323 | The ETF bought 446 new shares of DYN (DYNAGREEN EN.PR.GR.H YC 1). The shares were bought for an average price of 16.42 compared to the previous average buy price of 15.0497. This is 9.1% higher than average price of previous purchases of DYN. |
| OLMA - Olema Pharmaceuticals Inc | BUY | 244 @ USD 29.19 | USD 7,122 | The ETF bought 244 new shares of OLMA (Olema Pharmaceuticals Inc). The shares were bought for an average price of 29.19 compared to the previous average buy price of 13.3628. This is 118.4% higher than average price of previous purchases of OLMA. |
| SRPT - Sarepta Therapeutics Inc | BUY | 332 @ USD 21.31 | USD 7,075 | The ETF bought 332 new shares of SRPT (Sarepta Therapeutics Inc). The shares were bought for an average price of 21.31 compared to the previous average buy price of 29.9175. This is -28.8% lower than average price of previous purchases of SRPT. |
| RARE - Ultragenyx | BUY | 300 @ USD 23.5 | USD 7,050 | The ETF bought 300 new shares of RARE (Ultragenyx). The shares were bought for an average price of 23.5 compared to the previous average buy price of 35.4223. This is -33.7% lower than average price of previous purchases of RARE. |
| RARE - WISETFWTMRARETFP | BUY | 300 @ USD 23.5 | USD 7,050 | The ETF bought 300 new shares of RARE (WISETFWTMRARETFP). The shares were bought for an average price of 23.5 compared to the previous average buy price of 35.4223. This is -33.7% lower than average price of previous purchases of RARE. |
| CNTA - Centessa Pharmaceuticals PLC ADR | BUY | 300 @ USD 22.4 | USD 6,720 | The ETF bought 300 new shares of CNTA (Centessa Pharmaceuticals PLC ADR). The shares were bought for an average price of 22.4 compared to the previous average buy price of 19.7211. This is 13.6% higher than average price of previous purchases of CNTA. |
| HRMY - Harmony Biosciences Holdings | BUY | 180 @ USD 36.41 | USD 6,554 | The ETF bought 180 new shares of HRMY (Harmony Biosciences Holdings). The shares were bought for an average price of 36.41 compared to the previous average buy price of 33.5957. This is 8.4% higher than average price of previous purchases of HRMY. |
| GMAB - Genmab AS | BUY | 182 @ USD 33.85 | USD 6,161 | The ETF bought 182 new shares of GMAB (Genmab AS). The shares were bought for an average price of 33.85 compared to the previous average buy price of 28.4719. This is 18.9% higher than average price of previous purchases of GMAB. |
| AUPH - Aurinia Pharmaceuticals Inc | BUY | 412 @ USD 14.87 | USD 6,126 | The ETF bought 412 new shares of AUPH (Aurinia Pharmaceuticals Inc). The shares were bought for an average price of 14.87 compared to the previous average buy price of 11.6021. This is 28.2% higher than average price of previous purchases of AUPH. |
| VCEL - Vericel Corp Ord | BUY | 158 @ USD 38.57 | USD 6,094 | The ETF bought 158 new shares of VCEL (Vericel Corp Ord). The shares were bought for an average price of 38.57 compared to the previous average buy price of 39.7921. This is -3.1% lower than average price of previous purchases of VCEL. |
| ANIP - ANI Pharmaceuticals Inc | BUY | 70 @ USD 85.29 | USD 5,970 | The ETF bought 70 new shares of ANIP (ANI Pharmaceuticals Inc). The shares were bought for an average price of 85.29 compared to the previous average buy price of 76.0081. This is 12.2% higher than average price of previous purchases of ANIP. |
| NRIX - Nurix Therapeutics Inc | BUY | 316 @ USD 18.86 | USD 5,960 | The ETF bought 316 new shares of NRIX (Nurix Therapeutics Inc). The shares were bought for an average price of 18.86 compared to the previous average buy price of 14.8367. This is 27.1% higher than average price of previous purchases of NRIX. |
| LEGN - Legend Biotech Corp | BUY | 262 @ USD 22.11 | USD 5,793 | The ETF bought 262 new shares of LEGN (Legend Biotech Corp). The shares were bought for an average price of 22.11 compared to the previous average buy price of 32.091. This is -31.1% lower than average price of previous purchases of LEGN. |
| DVAX - Dynavax Technologies Corporation | BUY | 366 @ USD 15.62 | USD 5,717 | The ETF bought 366 new shares of DVAX (Dynavax Technologies Corporation). The shares were bought for an average price of 15.62 compared to the previous average buy price of 10.8845. This is 43.5% higher than average price of previous purchases of DVAX. |
| HROW - Harrow Health Inc | BUY | 116 @ USD 48.49 | USD 5,625 | The ETF bought 116 new shares of HROW (Harrow Health Inc). The shares were bought for an average price of 48.49 compared to the previous average buy price of 37.709. This is 28.6% higher than average price of previous purchases of HROW. |
| SNDX - Syndax Pharmaceuticals Inc | BUY | 270 @ USD 20.67 | USD 5,581 | The ETF bought 270 new shares of SNDX (Syndax Pharmaceuticals Inc). The shares were bought for an average price of 20.67 compared to the previous average buy price of 14.4663. This is 42.9% higher than average price of previous purchases of SNDX. |
| ZYME - Zymeworks Inc. Common Stock | BUY | 234 @ USD 23.63 | USD 5,529 | The ETF bought 234 new shares of ZYME (Zymeworks Inc. Common Stock). The shares were bought for an average price of 23.63 compared to the previous average buy price of 17.7768. This is 32.9% higher than average price of previous purchases of ZYME. |
| MNKD - MannKind Corp | BUY | 960 @ USD 5.58 | USD 5,357 | The ETF bought 960 new shares of MNKD (MannKind Corp). The shares were bought for an average price of 5.58 compared to the previous average buy price of 5.00903. This is 11.4% higher than average price of previous purchases of MNKD. |
| ARDX - Ardelyx Inc | BUY | 760 @ USD 7.04 | USD 5,350 | The ETF bought 760 new shares of ARDX (Ardelyx Inc). The shares were bought for an average price of 7.04 compared to the previous average buy price of 5.02366. This is 40.1% higher than average price of previous purchases of ARDX. |
| KNSA - Kiniksa Pharmaceuticals Ltd | BUY | 140 @ USD 37.92 | USD 5,309 | The ETF bought 140 new shares of KNSA (Kiniksa Pharmaceuticals Ltd). The shares were bought for an average price of 37.92 compared to the previous average buy price of 33.3297. This is 13.8% higher than average price of previous purchases of KNSA. |
| STOK - Stoke Therapeutics Inc | BUY | 178 @ USD 29.28 | USD 5,212 | The ETF bought 178 new shares of STOK (Stoke Therapeutics Inc). The shares were bought for an average price of 29.28 compared to the previous average buy price of 20.4269. This is 43.3% higher than average price of previous purchases of STOK. |
| PHVS - Pharvaris BV | BUY | 200 @ USD 25.65 | USD 5,130 | The ETF bought 200 new shares of PHVS (Pharvaris BV). The shares were bought for an average price of 25.65 compared to the previous average buy price of 25.8137. This is -0.6% lower than average price of previous purchases of PHVS. |
| AGIO - Agios Pharm | BUY | 182 @ USD 27.8 | USD 5,060 | The ETF bought 182 new shares of AGIO (Agios Pharm). The shares were bought for an average price of 27.8 compared to the previous average buy price of 33.5999. This is -17.3% lower than average price of previous purchases of AGIO. |
| TNGX - Tango Therapeutics Inc | BUY | 420 @ USD 11.69 | USD 4,910 | The ETF bought 420 new shares of TNGX (Tango Therapeutics Inc). The shares were bought for an average price of 11.69 compared to the previous average buy price of 7.78534. This is 50.2% higher than average price of previous purchases of TNGX. |
| NVCR - Novocure Ltd | BUY | 350 @ USD 13.8 | USD 4,830 | The ETF bought 350 new shares of NVCR (Novocure Ltd). The shares were bought for an average price of 13.8 compared to the previous average buy price of 15.3764. This is -10.3% lower than average price of previous purchases of NVCR. |
| BCRX - BioCryst Pharmaceuticals Inc | BUY | 658 @ USD 7.17 | USD 4,718 | The ETF bought 658 new shares of BCRX (BioCryst Pharmaceuticals Inc). The shares were bought for an average price of 7.17 compared to the previous average buy price of 8.00548. This is -10.4% lower than average price of previous purchases of BCRX. |
| INVA - Innoviva Inc | BUY | 234 @ USD 19.76 | USD 4,624 | The ETF bought 234 new shares of INVA (Innoviva Inc). The shares were bought for an average price of 19.76 compared to the previous average buy price of 19.6866. This is 0.4% higher than average price of previous purchases of INVA. |
| AMLX - Amylyx Pharmaceuticals Inc | BUY | 342 @ USD 13.52 | USD 4,624 | The ETF bought 342 new shares of AMLX (Amylyx Pharmaceuticals Inc). The shares were bought for an average price of 13.52 compared to the previous average buy price of 9.29031. This is 45.5% higher than average price of previous purchases of AMLX. |
| FTRE - Fortrea Holdings Inc. | BUY | 288 @ USD 15.96 | USD 4,596 | The ETF bought 288 new shares of FTRE (Fortrea Holdings Inc.). The shares were bought for an average price of 15.96 compared to the previous average buy price of 8.94569. This is 78.4% higher than average price of previous purchases of FTRE. |
| COLL - Collegium Pharmaceutical Inc | BUY | 98 @ USD 46.9 | USD 4,596 | The ETF bought 98 new shares of COLL (Collegium Pharmaceutical Inc). The shares were bought for an average price of 46.9 compared to the previous average buy price of 36.267. This is 29.3% higher than average price of previous purchases of COLL. |
| ELVN - Enliven Therapeutics Inc. | BUY | 182 @ USD 25.17 | USD 4,581 | The ETF bought 182 new shares of ELVN (Enliven Therapeutics Inc.). The shares were bought for an average price of 25.17 compared to the previous average buy price of 20.9718. This is 20.0% higher than average price of previous purchases of ELVN. |
| PGEN - Precigen Inc | BUY | 1,106 @ USD 4.14 | USD 4,579 | The ETF bought 1106 new shares of PGEN (Precigen Inc). The shares were bought for an average price of 4.14 compared to the previous average buy price of 3.05899. This is 35.3% higher than average price of previous purchases of PGEN. |
| IMCR - Immunocore Holdings Ltd | BUY | 136 @ USD 32.75 | USD 4,454 | The ETF bought 136 new shares of IMCR (Immunocore Holdings Ltd). The shares were bought for an average price of 32.75 compared to the previous average buy price of 34.2757. This is -4.5% lower than average price of previous purchases of IMCR. |
| NTLA - Intellia Therapeutics Inc | BUY | 360 @ USD 11.87 | USD 4,273 | The ETF bought 360 new shares of NTLA (Intellia Therapeutics Inc). The shares were bought for an average price of 11.87 compared to the previous average buy price of 11.4074. This is 4.1% higher than average price of previous purchases of NTLA. |
| QURE - Uniqure NV | BUY | 194 @ USD 21.98 | USD 4,264 | The ETF bought 194 new shares of QURE (Uniqure NV). The shares were bought for an average price of 21.98 compared to the previous average buy price of 23.6715. This is -7.1% lower than average price of previous purchases of QURE. |
| TSHA - Taysha Gene Therapies Inc | BUY | 858 @ USD 4.9 | USD 4,204 | The ETF bought 858 new shares of TSHA (Taysha Gene Therapies Inc). The shares were bought for an average price of 4.9 compared to the previous average buy price of 3.35286. This is 46.1% higher than average price of previous purchases of TSHA. |
| RLAY - Relay Therapeutics Inc | BUY | 542 @ USD 7.63 | USD 4,135 | The ETF bought 542 new shares of RLAY (Relay Therapeutics Inc). The shares were bought for an average price of 7.63 compared to the previous average buy price of 5.04566. This is 51.2% higher than average price of previous purchases of RLAY. |
| ANAB - AnaptysBio Inc | BUY | 86 @ USD 46.31 | USD 3,983 | The ETF bought 86 new shares of ANAB (AnaptysBio Inc). The shares were bought for an average price of 46.31 compared to the previous average buy price of 29.3969. This is 57.5% higher than average price of previous purchases of ANAB. |
| NVAX - Novavax Inc | BUY | 508 @ USD 7.78 | USD 3,952 | The ETF bought 508 new shares of NVAX (Novavax Inc). The shares were bought for an average price of 7.78 compared to the previous average buy price of 7.23246. This is 7.6% higher than average price of previous purchases of NVAX. |
| NVAX - Hana Microelectronics Public Company Limited | BUY | 508 @ USD 7.78 | USD 3,952 | The ETF bought 508 new shares of NVAX (Hana Microelectronics Public Company Limited). The shares were bought for an average price of 7.78 compared to the previous average buy price of 7.23246. This is 7.6% higher than average price of previous purchases of NVAX. |
| ABCL - Abcellera Biologics Inc | BUY | 930 @ USD 4.18 | USD 3,887 | The ETF bought 930 new shares of ABCL (Abcellera Biologics Inc). The shares were bought for an average price of 4.18 compared to the previous average buy price of 3.84181. This is 8.8% higher than average price of previous purchases of ABCL. |
| SANA - Sana Biotechnology Inc | BUY | 830 @ USD 4.67 | USD 3,876 | The ETF bought 830 new shares of SANA (Sana Biotechnology Inc). The shares were bought for an average price of 4.67 compared to the previous average buy price of 3.53726. This is 32.0% higher than average price of previous purchases of SANA. |
| XERS - Xeris Pharmaceuticals Inc | BUY | 520 @ USD 7.41 | USD 3,853 | The ETF bought 520 new shares of XERS (Xeris Pharmaceuticals Inc). The shares were bought for an average price of 7.41 compared to the previous average buy price of 6.30637. This is 17.5% higher than average price of previous purchases of XERS. |
| AMPH - Amphastar P | BUY | 144 @ USD 26 | USD 3,744 | The ETF bought 144 new shares of AMPH (Amphastar P). The shares were bought for an average price of 26 compared to the previous average buy price of 26.0289. This is -0.1% lower than average price of previous purchases of AMPH. |
| SVRA - Savara Inc | BUY | 636 @ USD 5.88 | USD 3,740 | The ETF bought 636 new shares of SVRA (Savara Inc). The shares were bought for an average price of 5.88 compared to the previous average buy price of 4.32768. This is 35.9% higher than average price of previous purchases of SVRA. |
| CSTL - Castle Biosciences Inc | BUY | 90 @ USD 40.75 | USD 3,668 | The ETF bought 90 new shares of CSTL (Castle Biosciences Inc). The shares were bought for an average price of 40.75 compared to the previous average buy price of 27.1025. This is 50.4% higher than average price of previous purchases of CSTL. |
| SPRY - Silverback Therapeutics Inc | BUY | 310 @ USD 11.09 | USD 3,438 | The ETF bought 310 new shares of SPRY (Silverback Therapeutics Inc). The shares were bought for an average price of 11.09 compared to the previous average buy price of 12.2893. This is -9.8% lower than average price of previous purchases of SPRY. |
| GRFS - Grifols SA ADR | BUY | 382 @ USD 8.93001 | USD 3,411 | The ETF bought 382 new shares of GRFS (Grifols SA ADR). The shares were bought for an average price of 8.93001 compared to the previous average buy price of 9.18007. This is -2.7% lower than average price of previous purchases of GRFS. |
| ORIC - Oric Pharmaceuticals Inc | BUY | 296 @ USD 11.52 | USD 3,410 | The ETF bought 296 new shares of ORIC (Oric Pharmaceuticals Inc). The shares were bought for an average price of 11.52 compared to the previous average buy price of 10.6397. This is 8.3% higher than average price of previous purchases of ORIC. |
| PHAT - Phathom Pharmaceuticals Inc | BUY | 222 @ USD 14.98 | USD 3,326 | The ETF bought 222 new shares of PHAT (Phathom Pharmaceuticals Inc). The shares were bought for an average price of 14.98 compared to the previous average buy price of 10.8365. This is 38.2% higher than average price of previous purchases of PHAT. |
| DAWN - Day One Biopharmaceuticals Inc | BUY | 314 @ USD 10.5 | USD 3,297 | The ETF bought 314 new shares of DAWN (Day One Biopharmaceuticals Inc). The shares were bought for an average price of 10.5 compared to the previous average buy price of 7.82368. This is 34.2% higher than average price of previous purchases of DAWN. |
| TBPH - Theravance Biopharma Inc | BUY | 156 @ USD 20.11 | USD 3,137 | The ETF bought 156 new shares of TBPH (Theravance Biopharma Inc). The shares were bought for an average price of 20.11 compared to the previous average buy price of 13.8659. This is 45.0% higher than average price of previous purchases of TBPH. |
| VTYX - Ventyx Biosciences Inc | BUY | 224 @ USD 13.86 | USD 3,105 | The ETF bought 224 new shares of VTYX (Ventyx Biosciences Inc). The shares were bought for an average price of 13.86 compared to the previous average buy price of 12.8782. This is 7.6% higher than average price of previous purchases of VTYX. |
| XNCR - Xencor Inc | BUY | 224 @ USD 13.21 | USD 2,959 | The ETF bought 224 new shares of XNCR (Xencor Inc). The shares were bought for an average price of 13.21 compared to the previous average buy price of 12.7008. This is 4.0% higher than average price of previous purchases of XNCR. |
| URGN - UroGen Pharma Ltd | BUY | 146 @ USD 19.54 | USD 2,853 | The ETF bought 146 new shares of URGN (UroGen Pharma Ltd). The shares were bought for an average price of 19.54 compared to the previous average buy price of 17.1782. This is 13.7% higher than average price of previous purchases of URGN. |
| ABUS - Arbutus Biopharma Corp | BUY | 604 @ USD 4.7 | USD 2,839 | The ETF bought 604 new shares of ABUS (Arbutus Biopharma Corp). The shares were bought for an average price of 4.7 compared to the previous average buy price of 3.89592. This is 20.6% higher than average price of previous purchases of ABUS. |
| RAPT - RAPT Therapeutics Inc | BUY | 86 @ USD 32.19 | USD 2,768 | The ETF bought 86 new shares of RAPT (RAPT Therapeutics Inc). The shares were bought for an average price of 32.19 compared to the previous average buy price of 33.5627. This is -4.1% lower than average price of previous purchases of RAPT. |
| PCRX - Pacira BioSciences, Inc. | BUY | 134 @ USD 20.65 | USD 2,767 | The ETF bought 134 new shares of PCRX (Pacira BioSciences, Inc.). The shares were bought for an average price of 20.65 compared to the previous average buy price of 23.9163. This is -13.7% lower than average price of previous purchases of PCRX. |
| PAHC - Phibro Animal Health Corporation | BUY | 66 @ USD 40.06 | USD 2,644 | The ETF bought 66 new shares of PAHC (Phibro Animal Health Corporation). The shares were bought for an average price of 40.06 compared to the previous average buy price of 31.8539. This is 25.8% higher than average price of previous purchases of PAHC. |
| VIR - Vir Biotechnology Inc | BUY | 426 @ USD 6.2 | USD 2,641 | The ETF bought 426 new shares of VIR (Vir Biotechnology Inc). The shares were bought for an average price of 6.2 compared to the previous average buy price of 5.94393. This is 4.3% higher than average price of previous purchases of VIR. |
| VIR - Vidrala S.A | BUY | 426 @ USD 6.2 | USD 2,641 | The ETF bought 426 new shares of VIR (Vidrala S.A). The shares were bought for an average price of 6.2 compared to the previous average buy price of 5.94393. This is 4.3% higher than average price of previous purchases of VIR. |
| IOVA - Iovance Biotherapeutics Inc | BUY | 1,184 @ USD 2.22 | USD 2,628 | The ETF bought 1184 new shares of IOVA (Iovance Biotherapeutics Inc). The shares were bought for an average price of 2.22 compared to the previous average buy price of 2.39882. This is -7.5% lower than average price of previous purchases of IOVA. |
| GERN - Geron Corporation | BUY | 1,962 @ USD 1.3 | USD 2,551 | The ETF bought 1962 new shares of GERN (Geron Corporation). The shares were bought for an average price of 1.3 compared to the previous average buy price of 1.44187. This is -9.8% lower than average price of previous purchases of GERN. |
| JANX - Janux Therapeutics Inc | BUY | 184 @ USD 13.72 | USD 2,524 | The ETF bought 184 new shares of JANX (Janux Therapeutics Inc). The shares were bought for an average price of 13.72 compared to the previous average buy price of 25.7913. This is -46.8% lower than average price of previous purchases of JANX. |
| ARVN - Arvinas Inc | BUY | 202 @ USD 12.13 | USD 2,450 | The ETF bought 202 new shares of ARVN (Arvinas Inc). The shares were bought for an average price of 12.13 compared to the previous average buy price of 10.0446. This is 20.8% higher than average price of previous purchases of ARVN. |
| KURA - Kura Oncology Inc | BUY | 272 @ USD 8.91 | USD 2,424 | The ETF bought 272 new shares of KURA (Kura Oncology Inc). The shares were bought for an average price of 8.91 compared to the previous average buy price of 8.38253. This is 6.3% higher than average price of previous purchases of KURA. |
| KALV - Kalvista Pharmaceuticals Inc | BUY | 158 @ USD 14.96 | USD 2,364 | The ETF bought 158 new shares of KALV (Kalvista Pharmaceuticals Inc). The shares were bought for an average price of 14.96 compared to the previous average buy price of 13.6384. This is 9.7% higher than average price of previous purchases of KALV. |
| PRME - Prime Medicine, Inc. Common Stock | BUY | 584 @ USD 3.99 | USD 2,330 | The ETF bought 584 new shares of PRME (Prime Medicine, Inc. Common Stock). The shares were bought for an average price of 3.99 compared to the previous average buy price of 3.87952. This is 2.8% higher than average price of previous purchases of PRME. |
| IRWD - Ironwood Pharmaceuticals Inc | BUY | 512 @ USD 4.52 | USD 2,314 | The ETF bought 512 new shares of IRWD (Ironwood Pharmaceuticals Inc). The shares were bought for an average price of 4.52 compared to the previous average buy price of 2.46135. This is 83.6% higher than average price of previous purchases of IRWD. |
| ZLAB - Zai Lab Ltd | BUY | 122 @ USD 18.82 | USD 2,296 | The ETF bought 122 new shares of ZLAB (Zai Lab Ltd). The shares were bought for an average price of 18.82 compared to the previous average buy price of 30.5822. This is -38.5% lower than average price of previous purchases of ZLAB. |
| PACB - Pacific Biosciences of California | BUY | 950 @ USD 2.35 | USD 2,233 | The ETF bought 950 new shares of PACB (Pacific Biosciences of California). The shares were bought for an average price of 2.35 compared to the previous average buy price of 1.74117. This is 35.0% higher than average price of previous purchases of PACB. |
| RGNX - Regenxbio Inc | BUY | 158 @ USD 13.76 | USD 2,174 | The ETF bought 158 new shares of RGNX (Regenxbio Inc). The shares were bought for an average price of 13.76 compared to the previous average buy price of 10.2673. This is 34.0% higher than average price of previous purchases of RGNX. |
| CGEM - Cullinan Oncology LLC | BUY | 182 @ USD 10.66 | USD 1,940 | The ETF bought 182 new shares of CGEM (Cullinan Oncology LLC). The shares were bought for an average price of 10.66 compared to the previous average buy price of 8.69033. This is 22.7% higher than average price of previous purchases of CGEM. |
| MGTX - MeiraGTx Holdings PLC | BUY | 244 @ USD 7.69 | USD 1,876 | The ETF bought 244 new shares of MGTX (MeiraGTx Holdings PLC). The shares were bought for an average price of 7.69 compared to the previous average buy price of 7.4239. This is 3.6% higher than average price of previous purchases of MGTX. |
| KROS - Keros Therapeutics Inc | BUY | 96 @ USD 19.26 | USD 1,849 | The ETF bought 96 new shares of KROS (Keros Therapeutics Inc). The shares were bought for an average price of 19.26 compared to the previous average buy price of 15.9815. This is 20.5% higher than average price of previous purchases of KROS. |
| REPL - Replimune Group Inc | BUY | 246 @ USD 7.30001 | USD 1,796 | The ETF bought 246 new shares of REPL (Replimune Group Inc). The shares were bought for an average price of 7.30001 compared to the previous average buy price of 9.17617. This is -20.4% lower than average price of previous purchases of REPL. |
| FULC - Fulcrum Therapeutics Inc | BUY | 170 @ USD 10.38 | USD 1,765 | The ETF bought 170 new shares of FULC (Fulcrum Therapeutics Inc). The shares were bought for an average price of 10.38 compared to the previous average buy price of 10.1373. This is 2.4% higher than average price of previous purchases of FULC. |
| PRTA - Prothena Corporation plc | BUY | 184 @ USD 9.26001 | USD 1,704 | The ETF bought 184 new shares of PRTA (Prothena Corporation plc). The shares were bought for an average price of 9.26001 compared to the previous average buy price of 9.49998. This is -2.5% lower than average price of previous purchases of PRTA. |
| MRVI - Maravai Lifesciences Holdings Inc | BUY | 458 @ USD 3.69 | USD 1,690 | The ETF bought 458 new shares of MRVI (Maravai Lifesciences Holdings Inc). The shares were bought for an average price of 3.69 compared to the previous average buy price of 2.98155. This is 23.8% higher than average price of previous purchases of MRVI. |
| SIGA - SIGA Technologies Inc | BUY | 236 @ USD 6.61001 | USD 1,560 | The ETF bought 236 new shares of SIGA (SIGA Technologies Inc). The shares were bought for an average price of 6.61001 compared to the previous average buy price of 6.62761. This is -0.3% lower than average price of previous purchases of SIGA. |
| GLPG - Galapagos NV ADR | BUY | 44 @ USD 34.03 | USD 1,497 | The ETF bought 44 new shares of GLPG (Galapagos NV ADR). The shares were bought for an average price of 34.03 compared to the previous average buy price of 29.828. This is 14.1% higher than average price of previous purchases of GLPG. |
| GLPG - Galapagos N.V. | BUY | 44 @ USD 34.03 | USD 1,497 | The ETF bought 44 new shares of GLPG (Galapagos N.V.). The shares were bought for an average price of 34.03 compared to the previous average buy price of 29.828. This is 14.1% higher than average price of previous purchases of GLPG. |
| LYEL - Lyell Immunopharma Inc | BUY | 64 @ USD 22.93 | USD 1,468 | The ETF bought 64 new shares of LYEL (Lyell Immunopharma Inc). The shares were bought for an average price of 22.93 compared to the previous average buy price of 7.65874. This is 199.4% higher than average price of previous purchases of LYEL. |
| AVXL - Anavex Life Sciences Corp | BUY | 290 @ USD 4.85001 | USD 1,407 | The ETF bought 290 new shares of AVXL (Anavex Life Sciences Corp). The shares were bought for an average price of 4.85001 compared to the previous average buy price of 7.82159. This is -38.0% lower than average price of previous purchases of AVXL. |
| ALT - Altitude Group Plc | BUY | 330 @ USD 4.24 | USD 1,399 | The ETF bought 330 new shares of ALT (Altitude Group Plc). The shares were bought for an average price of 4.24 compared to the previous average buy price of 4.87773. This is -13.1% lower than average price of previous purchases of ALT. |
| VNDA - Vanda Pharmaceuticals Inc | BUY | 184 @ USD 7.45001 | USD 1,371 | The ETF bought 184 new shares of VNDA (Vanda Pharmaceuticals Inc). The shares were bought for an average price of 7.45001 compared to the previous average buy price of 5.04436. This is 47.7% higher than average price of previous purchases of VNDA. |
| RCKT - Rocket Pharmaceuticals Inc | BUY | 360 @ USD 3.71001 | USD 1,336 | The ETF bought 360 new shares of RCKT (Rocket Pharmaceuticals Inc). The shares were bought for an average price of 3.71001 compared to the previous average buy price of 4.63701. This is -20.0% lower than average price of previous purchases of RCKT. |
| TRDA - Entrada Therapeutics Inc | BUY | 120 @ USD 10.82 | USD 1,298 | The ETF bought 120 new shares of TRDA (Entrada Therapeutics Inc). The shares were bought for an average price of 10.82 compared to the previous average buy price of 8.35361. This is 29.5% higher than average price of previous purchases of TRDA. |
| FDMT - 4D Molecular Therapeutics Inc | BUY | 168 @ USD 7.61001 | USD 1,278 | The ETF bought 168 new shares of FDMT (4D Molecular Therapeutics Inc). The shares were bought for an average price of 7.61001 compared to the previous average buy price of 7.84991. This is -3.1% lower than average price of previous purchases of FDMT. |
| ACIU - AC Immune Ltd | BUY | 338 @ USD 3.63 | USD 1,227 | The ETF bought 338 new shares of ACIU (AC Immune Ltd). The shares were bought for an average price of 3.63 compared to the previous average buy price of 2.63548. This is 37.7% higher than average price of previous purchases of ACIU. |
| ALLO - Allogene Therapeutics Inc | BUY | 742 @ USD 1.61 | USD 1,195 | The ETF bought 742 new shares of ALLO (Allogene Therapeutics Inc). The shares were bought for an average price of 1.61 compared to the previous average buy price of 1.36152. This is 18.3% higher than average price of previous purchases of ALLO. |
| BCYC - Bicycle Therapeutics Ltd | BUY | 160 @ USD 6.46999 | USD 1,035 | The ETF bought 160 new shares of BCYC (Bicycle Therapeutics Ltd). The shares were bought for an average price of 6.46999 compared to the previous average buy price of 8.0855. This is -20.0% lower than average price of previous purchases of BCYC. |
| EOLS - Evolus Inc | BUY | 206 @ USD 5 | USD 1,030 | The ETF bought 206 new shares of EOLS (Evolus Inc). The shares were bought for an average price of 5 compared to the previous average buy price of 8.44041. This is -40.8% lower than average price of previous purchases of EOLS. |
| AVIR - Atea Pharmaceuticals Inc | BUY | 286 @ USD 3.44 | USD 984 | The ETF bought 286 new shares of AVIR (Atea Pharmaceuticals Inc). The shares were bought for an average price of 3.44 compared to the previous average buy price of 3.25436. This is 5.7% higher than average price of previous purchases of AVIR. |
| ACRS - Aclaris Therapeutics Inc | BUY | 346 @ USD 2.67001 | USD 924 | The ETF bought 346 new shares of ACRS (Aclaris Therapeutics Inc). The shares were bought for an average price of 2.67001 compared to the previous average buy price of 2.71436. This is -1.6% lower than average price of previous purchases of ACRS. |
| AUTL - Autolus Therapeutics Ltd | BUY | 608 @ USD 1.44 | USD 876 | The ETF bought 608 new shares of AUTL (Autolus Therapeutics Ltd). The shares were bought for an average price of 1.44 compared to the previous average buy price of 1.72675. This is -16.6% lower than average price of previous purchases of AUTL. |
| OABI - OmniAb Inc. | BUY | 424 @ USD 1.92 | USD 814 | The ETF bought 424 new shares of OABI (OmniAb Inc.). The shares were bought for an average price of 1.92 compared to the previous average buy price of 1.8856. This is 1.8% higher than average price of previous purchases of OABI. |
| ARCT - Arcturus Therapeutics Holdings Inc | BUY | 98 @ USD 7.61001 | USD 746 | The ETF bought 98 new shares of ARCT (Arcturus Therapeutics Holdings Inc). The shares were bought for an average price of 7.61001 compared to the previous average buy price of 12.2327. This is -37.8% lower than average price of previous purchases of ARCT. |
| EDIT - Editas Medicine Inc | BUY | 330 @ USD 2.09 | USD 690 | The ETF bought 330 new shares of EDIT (Editas Medicine Inc). The shares were bought for an average price of 2.09 compared to the previous average buy price of 2.58305. This is -19.1% lower than average price of previous purchases of EDIT. |
| VYGR - Voyager Therapeutics Inc | BUY | 176 @ USD 3.82 | USD 672 | The ETF bought 176 new shares of VYGR (Voyager Therapeutics Inc). The shares were bought for an average price of 3.82 compared to the previous average buy price of 3.95233. This is -3.3% lower than average price of previous purchases of VYGR. |
| CABA - Cabaletta Bio Inc | BUY | 312 @ USD 2.08 | USD 649 | The ETF bought 312 new shares of CABA (Cabaletta Bio Inc). The shares were bought for an average price of 2.08 compared to the previous average buy price of 2.15093. This is -3.3% lower than average price of previous purchases of CABA. |
| HUMA - Humacyte Inc | BUY | 564 @ USD 1.1 | USD 620 | The ETF bought 564 new shares of HUMA (Humacyte Inc). The shares were bought for an average price of 1.1 compared to the previous average buy price of 1.94303. This is -43.4% lower than average price of previous purchases of HUMA. |
| CRBU - Caribou Biosciences Inc | BUY | 304 @ USD 1.56 | USD 474 | The ETF bought 304 new shares of CRBU (Caribou Biosciences Inc). The shares were bought for an average price of 1.56 compared to the previous average buy price of 1.6775. This is -7.0% lower than average price of previous purchases of CRBU. |
| - - | HOLD | 0 @ USD 0 | USD 0 | |
| IBRX - Immunitybio Inc | HOLD | 0 @ USD 3.95 | USD 0 | The current share valuation price of IBRX based on adjusted close was USD 3.95. The average price that IBRX shares were previous bought at was USD 2.62261. The current market price is 50.6% higher than average price they were purchased at. The value of the holding in IBRX has increased by USD 624,851 compared to the previous valuation of Immunitybio Inc however if the holding was sold on 2026-01-15 this would crystalise an overall loss. |
| THRD - Third Harmonic Bio Inc. | HOLD | 0 @ USD 0.0300173 | USD 0 | The current share valuation price of THRD based on adjusted close was USD 0.0300173. The average price that THRD shares were previous bought at was USD 5.04749. The current market price is -99.4% lower than average price they were purchased at. USD 0 compared to the previous valuation of Third Harmonic Bio Inc. however if the holding was sold on 2026-01-15 this would crystalise an overall loss. |